AK
Akhilesh Kumar Singh
About Akhilesh Kumar Singh
Data last updated:
Akhilesh Kumar Singh has 10 years in corporate governance. Holds Director role. Currently with 1 company, including Ebm Drugs & Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Ebm Drugs & Pharmaceuticals Private Limited at ₹1.63 Cr (FY 2021).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Ebm Drugs & Pharmaceuticals Private Limited U51909UP2016PTC086809 | Director | 30 Sep 2016 | 2016 | ₹1.63 Cr (FY 2021) | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Akhilesh Kumar Singh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akhilesh Kumar Singh
Akhilesh Kumar Singh has 10 years in corporate governance. Holds Director role. Currently with 1 company, including Ebm Drugs & Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Ebm Drugs & Pharmaceuticals Private Limited at ₹1.63 Cr (FY 2021).
Akhilesh Kumar Singh is associated with 1 company as Director, including Ebm Drugs & Pharmaceuticals Private Limited (₹1.63 Cr).
Akhilesh Kumar Singh has expertise in General Business.
Akhilesh Kumar Singh has 10 years in corporate governance.
By reported revenue, the largest current company of Akhilesh Kumar Singh is Ebm Drugs & Pharmaceuticals Private Limited, with revenue of ₹1.63 Cr (FY 2021).
Akhilesh Kumar Singh currently holds positions at 1 company: Ebm Drugs & Pharmaceuticals Private Limited (₹1.63 Cr).